SNDL Inc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), SNDL Inc reported revenue of $946.4M (+2.8% year on year) and net income of ($15.8M) (+83.6% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net revenue | $946.4M | $920.4M | — | $712.2M |
| Cost of sales | $687.8M | $680.1M | — | $558.1M |
| Gross profit | $258.6M | $240.3M | — | $140.4M |
| Investment income | $7.8M | $15.6M | — | ($65.2M) |
| Share of loss of equity-accounted investees | ($3.6M) | ($65.5M) | — | ($43.0M) |
| General and administrative | $182.2M | $187.2M | — | $140.2M |
| Sales and marketing | $14.6M | $12.0M | — | $8.4M |
| Research and development | $489.0K | $346.0K | — | $2.4M |
| Depreciation and amortization | $51.9M | $54.3M | — | $40.9M |
| Share-based compensation | $13.9M | $20.0M | — | $9.7M |
| Restructuring costs | $3.3M | $2.7M | — | ($670.0K) |
| Asset impairment, net | $2.6M | $17.3M | — | $196.0M |
| Loss on disposition of assets | $182.0K | $370.0K | — | ($94.0K) |
| Operating loss | ($6.3M) | ($103.8M) | — | ($347.8M) |
| Other expenses, net | ($9.4M) | ($1.8M) | — | — |
| Loss before income tax | ($15.8M) | ($105.6M) | — | ($379.8M) |
| Income tax recovery | $0 | $9.4M | — | $7.3M |
| Equity-accounted investees - share of other comprehensive (loss) income | ($19.2M) | $31.5M | — | $24.6M |
| Investments at fair value through other comprehensive income ("FVOCI") - change in fair value | $5.4M | $1.9M | — | — |
| Owners of the company | ($15.8M) | ($94.8M) | — | ($335.1M) |
| Net loss | ($15.8M) | ($96.2M) | — | ($372.4M) |
| Owners of the company | ($29.6M) | ($61.4M) | — | ($310.5M) |
| Non-controlling interest | $0 | ($1.4M) | — | ($37.3M) |
| Comprehensive loss | ($29.6M) | ($62.9M) | — | ($347.8M) |
| Basic net loss per common share attributable to owners of the Company | -$0.06 | -$0.36 | — | — |
| Diluted net loss per common share attributable to owners of the Company | -$0.06 | -$0.36 | — | — |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $252.2M | $218.4M | $195.0M | $279.6M |
| Restricted cash | $20.1M | $19.8M | $19.9M | $19.3M |
| Marketable securities | $84.0K | $139.0K | $225.0K | $21.9M |
| Accounts receivable | $27.6M | $28.1M | $27.1M | $22.6M |
| Biological assets | $3.1M | $1.2M | $429.0K | $3.5M |
| Inventory | $126.9M | $127.9M | $129.1M | $127.8M |
| Prepaid expenses and deposits | $15.6M | $16.9M | $22.5M | $10.1M |
| Investments | $484.0K | $27.6M | $3.4M | $6.6M |
| Assets held for sale | $746.0K | $19.1M | $6.4M | $6.4M |
| Net investment in subleases | $2.8M | $2.8M | $3.0M | $3.7M |
| Current assets | $449.6M | $461.8M | $406.9M | $501.5M |
| Long-term deposits and receivables | $4.5M | $3.7M | $4.8M | $8.6M |
| Right of use assets | $138.4M | $115.4M | $129.7M | $134.2M |
| Property, plant and equipment | $151.9M | $145.8M | $152.9M | $143.4M |
| Net investment in subleases | $11.6M | $15.4M | $18.4M | $19.6M |
| Intangible assets | $58.5M | $61.3M | $73.1M | $74.9M |
| Investments | $11.6M | $8.4M | $29.7M | $90.7M |
| Equity-accounted investees | $385.5M | $413.1M | $538.3M | $519.3M |
| Goodwill | $124.2M | $124.2M | $119.3M | $67.3M |
| Total assets | $1.3B | $1.3B | $1.5B | $1.6B |
| Accounts payable and accrued liabilities | $56.7M | $56.3M | $68.2M | $48.2M |
| Current lease liabilities | $35.5M | $34.3M | $30.5M | $30.2M |
| Derivative warrants | $0 | $26.0K | $4.4M | $11.0M |
| Current liabilities | $92.2M | $90.6M | $103.1M | $89.4M |
| Lease liabilities | $134.5M | $118.0M | $136.5M | $139.6M |
| Other liabilities | $8.0M | $7.3M | $4.2M | $2.7M |
| Total liabilities | $234.7M | $215.9M | $243.8M | $231.7M |
| Share capital | $2.3B | $2.3B | $2.4B | $2.3B |
| Warrants | $306.0K | $667.0K | $2.3M | $2.3M |
| Contributed surplus | $54.0M | $57.2M | $73.0M | $69.0M |
| Accumulated deficit | ($1.3B) | ($1.3B) | ($1.3B) | ($1.1B) |
| Accumulated other comprehensive income | $38.9M | $52.8M | $19.4M | $32.2M |
| Total shareholders’ equity | $1.1B | $1.1B | $1.2B | $1.3B |
| Total liabilities and shareholders’ equity | $1.3B | $1.3B | $1.5B | $1.6B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net loss for the period | ($15.8M) | ($96.2M) | — | — |
| Income tax recovery | $0 | ($9.4M) | — | ($7.3M) |
| Interest and fee income | ($7.4M) | ($15.6M) | — | — |
| Change in fair value of biological assets | ($2.3M) | ($892.0K) | — | $1.3M |
| Change in fair value of inventory sold | $1.3M | — | — | — |
| Share-based compensation | $13.9M | $20.0M | — | $9.7M |
| Depreciation and amortization | $56.3M | $56.7M | — | $47.3M |
| Loss on disposition of assets | $182.0K | $370.0K | — | $94.0K |
| Inventory impairment and obsolescence | $2.7M | $3.7M | — | $7.0M |
| Finance costs, net | $6.7M | $7.2M | — | $41.3M |
| Change in estimate of fair value of derivative warrants | ($26.0K) | ($4.4M) | — | ($10.8M) |
| Unrealized foreign exchange loss | $614.0K | $108.0K | — | ($16.0K) |
| Transaction costs | $0 | $164.0K | — | — |
| Bargain purchase gain | $0 | ($5.5M) | — | — |
| Asset impairment, net | $2.6M | $17.3M | — | $196.0M |
| Share of loss of equity-accounted investees | $3.6M | $65.5M | — | $43.0M |
| Unrealized (gain) loss on marketable securities | ($378.0K) | $86.0K | — | $65.6M |
| Additions to marketable securities | $433.0K | — | — | ($3.5M) |
| Income distributions from equity-accounted investees | $68.0K | $10.7M | — | $1.7M |
| Interest received | $7.1M | $12.5M | — | $13.4M |
| Change in non-cash working capital | $1.4M | ($7.4M) | — | ($22.1M) |
| Net cash provided by operating activities | $70.9M | $54.9M | — | ($6.7M) |
| Additions to property, plant and equipment | ($12.8M) | ($8.6M) | — | ($10.7M) |
| Additions to intangible assets | $0 | ($2.4M) | — | ($197.0K) |
| Additions to investments | ($16.4M) | — | — | ($75.6M) |
| Principal payments from investments | $27.5M | — | — | — |
| Proceeds from disposal of investments | $18.1M | — | — | — |
| Capital refunds from equity-accounted investees | $0 | — | — | — |
| Capital distributions from equity-accounted investees | $4.7M | $89.8M | — | $0 |
| Proceeds from disposal of property, plant and equipment | $813.0K | $734.0K | — | $4.0M |
| Acquisitions, net of cash acquired | ($3.0M) | ($39.6M) | — | ($28.6M) |
| Change in non-cash working capital | ($1.4M) | $383.0K | — | $74.0K |
| Net cash provided by investing activities | $17.5M | $17.8M | — | ($230.2M) |
| Change in restricted cash | ($267.0K) | $76.0K | — | $7.7M |
| Payments on lease liabilities, net | ($39.2M) | ($37.0M) | — | ($27.7M) |
| Repurchase of common shares | -15.3M | -13.2M | — | -13.4M |
| Proceeds from issuance of shares, net of costs | 0 | -59.0K | — | — |
| Issuance of common shares by subsidiaries | 0 | 174.0K | — | — |
| Change in non-cash working capital | $373.0K | $621.0K | — | $1.6M |
| Net cash used in financing activities | ($54.5M) | ($49.4M) | — | ($41.8M) |
| Change in cash and cash equivalents | $33.9M | $23.3M | — | ($278.7M) |
| Cash and cash equivalents, beginning of period | $218.4M | $195.0M | — | $558.3M |
| Cash and cash equivalents, end of period | $252.2M | $218.4M | $195.0M | — |
SNDL Inc score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.